Abstract:
The present invention deals with a mycoherbicidal isolate of Setosphaeria monoceras sp. or extracts obtained there-from, useful for the control of Water hyacinth. The present invention also discloses biological control compositions comprising fungal isolate extract formulated in a growth medium for maintaining the viability of extract when the biological control composition is applied to weed. The present invention also discloses methods of screening fungal isolate to determine if they exhibit biocontrol activity. The present invention also discloses use of Setosphaeria monoceras strain. In yet a further aspect the invention relates to use of an Setosphaeria strain for producing a herbicidal agent effective for controlling growth of water hyacinth plants. The strain used preferably is a strain having the characterizing features of Setosphaeria strain AGWH# 11 as deposited at IMTECH under ac-cession number MTCC 597 4. The present invention to provide the 1 Ss rRNA sequence analysis showed 96% nucleotide similarity of the Fungi to Setosphaeria monoceras. (AGBIO designated AGWH#1 1/NCIMI370/MTCC 5974) but also indicated nucleotide variation of this fungus from other known genus of Bipolaris, Pleosporaceae, Cochiliobolus, Altemaria including an environmentally acceptable alternative to synthetic chemical herbicides for the control of weeds, such as Water hyacinth. The present invention also discloses methods of whole genome study of strain.
Abstract:
A data mining and analysis system which analyzes a database of wellbore-related data in order to determine those predictor variables which influence or predict well performance.
Abstract:
Compounds of Formula (I) and pharmaceutically acceptable salts thereof in which X 1 , X 2 , X 3 , L, R 3 , R 4 , R 5 , R 7 and n have the meanings given in the specification, are modulators of GPR119 and are useful in the treatment or prevention of diseases such as such as, but not limited to, type 2 diabetes, diabetic complications, symptoms of diabetes, metabolic syndrome, obesity, dyslipidemia, and related conditions.
Abstract:
Embodiments of the present invention include methods and compositions for ameliorating cancer. Some embodiments include methods and compositions for ameliorating pancreatic cancer targeting the CXCR4 receptor and the CXCL12 ligand.
Abstract:
Compounds of Formula (I) and pharmaceutically acceptable salts thereof in which X 1 , X 2 , L, R 3 , R 4 , R 5 , R 7 and n have the meanings given in the specification, are modulators of GPR119 and are useful in the treatment or prevention of diseases such as such as, but not limited to, type 2 diabetes, diabetic complications, symptoms of diabetes, metabolic syndrome, obesity, dyslipidemia, and related conditions.
Abstract:
Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which X 1 , X 2 , L, R 3 , R 4 , R 5 , R 6 , R 6a , R 7 , R 9 , R 9a , and n have the meanings given in the specification, are modulators of GPR119 and are useful in the treatment or prevention of diseases such as such as, but not limited to, type 2 diabetes, diabetic complications, symptoms of diabetes, metabolic syndrome, obesity, dyslipidemia, and related conditions.
Abstract:
Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.
Abstract:
Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes meilitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.
Abstract:
For ion-mode plasma containment, a toroidal vacuum vessel (322) has a major radius (208) and a minor radius (212). The toroidal vacuum vessel (322) is filled with a gas (391) having an initial particle density. An ionizing device (341) ionizes the gas (391) into a plasma (400). A transformer inductively (326) drives a toroidal particle current (332) comprising an ion current and an electron current about a toroidal axis. The toroidal particle current (322) heats the plasma (400) and generates a poloidal magnetic field (373). Field coils (414) wound poloidally about the toroidal vacuum vessel (322) generate a toroidal magnetic field (371). The toroidal magnetic field (371) at a wall of the toroidal vacuum vessel (322) is adjusted to satisfy a boundary condition for a minimum-energy. The plasma (400) is contained by the radial electric field, the poloidal magnetic field (373), and the toroidal magnetic field (371) within the toroidal vacuum vessel (322) in the minimum-energy state.
Abstract:
A network comprising a component configured to update an active set (AS) of cells based on a collective consideration of a plurality of cell measurement reports received during radio reconfiguration. Also included is a user equipment (UE), comprising a component configured such that the UE combines a plurality of cell measurement reports triggered briefly before and/or during radio reconfiguration, the combined measurement report used to update an AS of cells. Also included is a method comprising transmitting a radio bearer reconfiguration message, receiving a plurality of cell measurement reports, receiving a radio bearer reconfiguration complete message, and updating a plurality of AS cells using the combined cell measurement reports. Also included is a method comprising receiving a radio bearer reconfiguration message, obtaining a plurality of cell measurement reports, and sending a combined cell measurement report based on the cell measurement reports.